Providence Clinical Research

We are opening the adolescent (age 12 - 17) extension for the Novavax COVID vaccine study next week (May 3rd) for ONLY ONE WEEK. We have 30 slots left. Call Erika at (818) 558-7555 today!

I just want to thank all of our 400+ patients who participated in the Pfizer and Novavax vaccine studies with us. You did a great job! Think about all of the people you have helped! I want to give you, our patients, a heads-up. We will be opening the adolescent (age 12 - 17) extension for the Novavax vaccine study on May 3rd and will be enrolling for ONLY ONE WEEK. We can enroll about 40 participants. If your young person (age 12 - 17) would like to participate and you are ...willing to assist them with this, call Erika at 818 558-7555 to learn more and get scheduled. Thanks for all you do, Dr. Teresa

Enrollment has just opened at our site! Call Erika at 818 558-7555 to learn more. Enrollment will close in just weeks so don't wait.

VOLUNTEER & MAKE A DIFFERENCE Currently, there are no approved vaccines available to prevent COVID-19, and the disease has spread across the world. Each and every person involved in clinical research plays a powerful role. Volunteering for this study can make a difference as we try to find a potential vaccine to prevent COVID-19. Call Erika at 818 558-7555 to learn more.

Press Release August 16, 2020 11:00 PM PDT Providence Clinical Research Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19 Teresa S. Sligh, MD will lead the Providence Clinical Research study program.... Potential participants can contact Erika at (818) 558-7555 to learn more about local enrollment criteria. North Hollywood, CA August 16, 2020 Providence Clinical Research today announced plans to participate as a study site for, and begin enrolling participants into, the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2, the virus causing the current global pandemic. Providence Clinical Research study site is one of more than 120 clinical investigational sites around the world that will collectively enroll up to 30,000 participants. The team at Providence Clinical Research is very happy to be able to offer this study to our patients and research participants. We are honored to be able to contribute to this important effort., - Teresa Sligh, MD About the Phase 2/3 Study The Phase 2/3 study is an event driven trial that will continue enrollment on a rolling basis, enroll up to 30,000 participants at more than 120 clinical investigational sites around the world, in non-pregnant adults 18-85 years old. The Phase 2/3 trial is designed as a 1:1 investigational vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The trial’s primary endpoints will be prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunization, and prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2. Secondary endpoints include prevention of severe COVID-19 in those groups. People interested in participating in the study through the Providence Clinical Research site can visit www.providenceclinical.com or call (818) 558-7555 to find out more. About Providence Clinical Research Providence Clinical Research is an independent research site that has been conducting clinical research in Los Angeles for more than 16 years. Providence Clinical Research Contacts: Erika Mendoza (818) 558-7555 See more

Enrollment has just opened at our site! Call Erika at 818 558-7555 to learn more. Enrollment will close in just weeks so don't wait.

Press Release August 16, 2020 11:00 PM PDT Providence Clinical Research Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19 Teresa S. Sligh, MD will lead the Providence Clinical Research study program.... Potential participants can contact Erika at (818) 558-7555 to learn more about local enrollment criteria. North Hollywood, CA August 16, 2020 Providence Clinical Research today announced plans to participate as a study site for, and begin enrolling participants into, the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2, the virus causing the current global pandemic. Providence Clinical Research study site is one of more than 120 clinical investigational sites around the world that will collectively enroll up to 30,000 participants. The team at Providence Clinical Research is very happy to be able to offer this study to our patients and research participants. We are honored to be able to contribute to this important effort., - Teresa Sligh, MD About the Phase 2/3 Study The Phase 2/3 study is an event driven trial that will continue enrollment on a rolling basis, enroll up to 30,000 participants at more than 120 clinical investigational sites around the world, in non-pregnant adults 18-85 years old. The Phase 2/3 trial is designed as a 1:1 investigational vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The trial’s primary endpoints will be prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunization, and prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2. Secondary endpoints include prevention of severe COVID-19 in those groups. People interested in participating in the study through the Providence Clinical Research site can visit www.providenceclinical.com or call (818) 558-7555 to find out more. About Providence Clinical Research Providence Clinical Research is an independent research site that has been conducting clinical research in Los Angeles for more than 16 years. Providence Clinical Research Contacts: Erika Mendoza (818) 558-7555 See more

During this very challenging time with the COVID-19 virus, we want to reassure you that the PCR team is doing everything we can to ensure the safety of our wonderful study participants: - extremely diligent cleaning protocols, - only one person in the waiting room at a time, - each person goes promptly into an exam room, - minimized visit times, ... - private Lyft rides for patients as needed, - we are requesting approval to conduct visits virtually as much as is possible. Your safety comes first. We are continually brainstorming how to best serve and protect our participants. Please let us know if there is anything else we can do to meet your needs as you participate in a study. God bless us all as we face, and pull through, this crisis. Please stay safe and wash your hands! Drs. Scott and Teresa Sligh

Providence Clinical Research was just approached to apply to be considered as a research site for multiple upcoming COVID-19 vaccine studies. What do you think? Would you consider participating in a vaccine study?

Lead by example and share healthy habits, like effective handwashing, with family, friends, and coworkers. Handwashing is a practical skill that you can easily ...learn and practice every day to #PrepYourHealth. It takes around 20 seconds, and can be done in 5 simple steps. Learn how: http://ow.ly/vT5O30qnMLZ See more

Caregivers: Be aware that older adults and people who have severe chronic medical conditions like heart, lung, or kidney disease seem to be at higher risk for m...ore serious COVID-19 illness. Learn about actions you can take to help protect their health and reduce their risk of COVID-19 infection: https://bit.ly/38ofRQc See more

While CDC considers COVID-19 a serious situation and is taking preparedness measures, the immediate health risk in the U.S. from the new coronavirus (COVID-19, ...previously called 2019-nCoV) is thought to be low at this time, based on what we know. Everyone should always take simple daily precautions to help prevent the spread of respiratory illnesses. To learn more about prevention, see https://bit.ly/37Ay6Cm.

Moderate to severe psoriasis? Compensation up to $1600. Call Erika to learn about our psoriasis studies at (818) 558-7555!

Thank you to our patients who have invested their time in participating in clinical research studies. You have done your community a great service by representing them for the therapies of tomorrow. Hopefully there is help on the horizon to make it a little easier for you to participate. The PCR family and I appreciate all that you do. - Dr. T

Moderate to severe psoriasis? Compensation up to $1600. Call Erika to learn about our psoriasis studies at (818) 558-7555!

This is the single best thing you can do to protect against contagious illnesses.

Holiday decorations, such as candles, can increase your risk for a home fire. The U.S. Fire Administration recommends placing candles at least 12 inches away fr...om anything that burns. It's also a good time to brush up on your practical skills. Learn how to use a fire extinguisher to #PrepYourHealth in case of an emergency. Remember the acronym P.A.S.S. It stands for Pull, Aim, Squeeze, Sweep. Learn more: http://ow.ly/ai2H30pTvNj See more

Participate. Make sure you are represented. Contact us at 818 558-7555 to learn about our current studies. We are proud to be one of the best sites in the US for diversity.